Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Optimi Health ( (TSE:OPTI) ) has shared an update.
Optimi Health has begun the first MDMA-assisted treatments of 2026 at an expanded network of authorized clinics in Australia, under the country’s Authorised Prescriber Scheme. The company is supplying its 40 mg and 60 mg MDMA capsules directly to clinics, maintaining manufacturing oversight and cost control while supporting a scalable model for regulated psychedelic therapy.
The rollout aligns with growing institutional support in Australia, including a veterans rehabilitation plan that backs psychedelic-assisted therapy for PTSD. With real-world evidence on patient outcomes being collected by the Australian National University and no serious adverse events reported in Scheme data as of late 2025, the initiative strengthens Optimi’s position in the emerging market for MDMA-assisted PTSD treatment, particularly among veterans and first responders.
The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.34 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.
Spark’s Take on TSE:OPTI Stock
According to Spark, TipRanks’ AI Analyst, TSE:OPTI is a Neutral.
The score is primarily held down by weak financial performance (declining small revenue, negative margins, persistent losses and cash burn, and higher leverage). Technicals provide only modest support with a neutral momentum profile and price above the 200-day average, while valuation is constrained by negative earnings (negative P/E) and no dividend yield data.
To see Spark’s full report on TSE:OPTI stock, click here.
More about Optimi Health
Optimi Health Corp. is a Health Canada-licensed, GMP-compliant pharmaceutical manufacturer specializing in prescribed psychedelic treatments for mental health conditions. The company produces validated MDMA and botanical psilocybin products from two facilities in British Columbia, supplying active ingredients and finished dosage forms to regulated channels in markets such as Australia and Canada.
Average Trading Volume: 79,830
Technical Sentiment Signal: Buy
Current Market Cap: C$33.75M
Find detailed analytics on OPTI stock on TipRanks’ Stock Analysis page.